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Extracellular matrix accumulation in immune-mediated
tubulointerstitial injury
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Extracellular matrix accumulation in immune-mediated tubulointersti-
ted injury. The accumulation of excessive extracellular matrix (ECM)
following tubular injury likely represents an imbalance between ECM
production and degradation. We assessed the temporal relationship
between the accumulation of ECM, cell adhesion molecules, matrix
degrading proteinases, and their inhibitors in a rat model of anti-tubular
basement membrane (TBM) antibody-associated tubulointerstitial ne-
phritis (TIN) by the RNase protection assay and immunohistochemis-
try. There was an increase in the steady state expression of fibronectin
(FN) and a2(IV) collagen mRNAs beginning on day 7 with the onset of
neutrophil infiltration. An increase in a1(III) collagen and a1-integrin did
not occur until days 9 and 10, respectively, at which time mononuclear
leukocytes were the predominant infiltrating cell. Increased levels of
FN, a,(III), a,(IV) and a1-integrin mRNAs occurred through day 14.
By immunohistochemistry, increased accumulation of collagen IV,
heparan sulfate proteoglycan, and laminin were detected along the
thickened TBM; collagens I and III were immunolocalized within the
tubulointerstitium, while FN was present in both the TBM and inter-
stitium in rats with TIN on day 14. The increase in matrix accumulation
was associated with little or no increase in proteinases. u-PA transcripts
fell beginning on day 8, with recovery to control values by day 12.
Transin mRNA was found at low levels only on days 8 and 9, and the
protein could not be detected by Western blotting. In contrast, these
changes were associated with an increase in proteinase inhibitors, so
that TIMP and PAl-I mRNAs increased beginning on day 7 and
persisted through day 14. PAI-l mRNA correlated with biologic activ-
ity, while TIMP was immunolocalized within the peritubular endothe-
lium and infiltrating leukocytes. These data demonstrate a temporal
association between ECM accumulation, a minimal change in protein-
ase, and an increase in proteinase inhibitors.
Tubulointerstitial fibrosis, a sequela of anti-tubular basement
membrane (TBM) antibody-associated tubulointerstitial nephri-
tis (TIN), results from extracellular matrix (ECM) accumulation
in response to renal injury. Excessive matrix accumulation
presumably represents an imbalance between rates of ECM
production and activation of proteolytic enzymes which func-
tion to degrade matrix components. The physiologically impor-
tant matrix degrading proteinases are a family of enzymes
collectively termed the metalloproteinases, since they contain a
zinc ion and can be inhibited by chelating agents [1]. They have
been subdivided into three subclasses, although an overlap of
enzymatic activity exists. These include interstitial collagenase,
gelatinase (type IV collagenases), and stromelysinltransin [I].
The metalloproteinases are secreted as latent proenzymes
which must be activated by plasmin, a cleavage product of
plasminogen [2, 3]. The latter depends upon the activity of
urokinase plasminogen activator (u-PA) [4], the activity of
which is tightly controlled by plasminogen activator inhibitor-l
(PAl-i) [5]. Plasmin-activated stromelysin/transin is autoprote-
olytic, thereby generating the active enzyme. In addition, the
activation of collagenase by plasmin enables this enzyme to be
cleaved by stromelysin/transin, resulting in a five- to eight-fold
increase in collagenase activity [6]. The activities of the metal-
loproteinases are tightly regulated at the transcriptional level
and by serum and tissue proteinase inhibitors [7, 8]. These
include broad spectrum serum inhibitors such as a2-macroglob-
ulin and a specific family of tissue inhibitors of metalloprotein-
ase (TIMP) [9].
Growth factors are believed to contribute to ECM accumu-
lation by altering the balance between matrix synthesis and
degradation [10]. For example, transforming growth factor /3
(TGF-J31) increases interstitial (types I and III) collagen, FN,
and proteoglycan synthesis [11—13]. Concomitantly, growth
factors inhibit the proteolytic degradation of the newly depos-
ited matrix. This is achieved by two distinct mechanisms which
include increasing the synthesis and secretion of proteinase
inhibitors and a concurrent decrease in the expression of
proteinases [10]. Thus, TGF-/3 induces TIMP expression while
inhibiting the transcription of stromelysin and collagenase in
cultured fibroblasts [14].
These studies in vitro suggest that similar mechanisms may
contribute to the pathogenesis of immune-mediated tubuloin-
terstitial fibrosis. We have preliminary data demonstrating
increased expression of several growth factors including basic
fibroblast growth factor, platelet-derived growth factor-B
(PDGF) and TGF-/3 and -a in anti-TBM antibody-associated
TIN [15]. To expand upon these observations, we studied the
temporal relationship of the ECM components (FN, laminin,
heparan sulfate proteoglycan (HSPG), and types I, III and IV
collagen), the cell adhesion molecule (a1-integrin), the protein-
ases (u-PA and transin/stromelysin), and the proteinase inhibi-
tors (PAl-i and TIMP).
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Experimental design
Bovine cortical TBM was prepared as previously described
[16]. Twenty-one female Brown Norway (BIN) rats (Scripps
Breeding Colony) were immunized in the tail base with 100 rg
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of bovine TBM in complete Freund's adjuvant with 4 mg of
dried Mycobacterium tuberculosis, H37Ra strain (DIFCO Lab-
oratories, Detroit, Michigan, USA). In addition, they received
Bordetella pertussis vaccine (Massachusetts Public Health Bi-
ologics Laboratory, Boston, Massachusetts, USA) containing
approximately 22.2 x 108 cells in a single intradermal flank
injection. Control animals (N = 21) were immunized with
ovalbumin (100 pjg) and the same adjuvants. Three rats from the
experimental and control groups were euthanized on days 3, 7,
8, 9, 10, 12, and 14. A second group of rats (N = 3) was
immunized in a similar manner and was euthanized on days 8
and 14 for immunohistochemistry.
Morphologic studies
Renal tissue was fixed in zinc-formalin solution or snap-
frozen in Tissue-Tek (Miles Inc., Elkhart, Indiana, USA) with
liquid nitrogen at sacrifice. Histologic examination was per-
formed on paraffin sections (2 to 3 m) stained with the
periodic-acid Schiff reaction and hematoxylin counterstain.
Immunocytochemical studies were performed on 3 to 4 m
frozen sections that had been fixed with acetone and blocked
with a 1:20 dilution of normal goat serum. They were then
incubated with the primary antibody which included rabbit
anti-rat heparan sulfate proteoglycan core protein (gift from Dr.
Y. Kanwar, Northwestern University, Chicago, Illinois, USA),
rabbit polyclonal antibodies to laminin, and rat types I, III and
IV collagen (gift from Dr. T. Yamamoto, Niigata University,
Niigata, Japan) for one hour. This was followed by incubating
with horseradish peroxidase conjugated goat anti-rabbit IgG
antibody (DAKO Inc., Carpinteria, California, USA) which had
been adsorbed with rat serum. The sections were developed
with 3,3'-diaminobenzidine tetrahydrochloride (Sigma Chemi-
cal Co., St. Louis, Missouri, USA) and hydrogen peroxide.
Cell culture
Chinese hamster ovary (CHO) cells transfected with the
eDNA for rat transin (gift of Dr. L. Matrisian, Vanderbilt
University, Nashville, Tennessee, USA) were cultured in
RPMI 1640 containing 10% fetal calf serum [17]. After two
passages, the cells were lysed with 4 M guanidium thiocyanate
(GTC) and RNA was prepared by phenol/chloroform extrac-
tion, as described [181.
Quantitation of steady state mRNA
PCR cloning. The cloning of the u-PA cDNA segment by
PCR has been described previously [19]. The Genalign program
(Intelligenetics, Inc., Mountain View, California, USA) was
used for selecting conserved regions of the cDNA for FN,
a2(IV)collagen, tenascin and TIMP. The sequences of the
primers were:
FN 5' primer: 5'-GTGGAGTATGTGGTFAGTGTC-3'
3' primer: 5'-GTCTGCTFGTCAATGTGTCCUG-3'
a2(IV) 5' primer: 5'-CCTGGCCCTGTGGGCATGAAAG-3'
3' primer: 5'-GGACTCCGATGTCTCCCTFGAC-3'
TIMP 5' primer: 5'-ACCACCTTATACCAGCGTrA-3'
3' primer: 5'-AAACAGGGAAACACTGTGCA-3'
Tenascin 5' primer: 5'-ATGACCTCTGATGG(N)GGTGGATG-3'
3' primer: 5'-GTGGAGAAGGATCT(N)CCATFGTG-3'
The cDNA for FN and a2(IV) were cloned from liver and
fetal kidney mRNA, respectively, by RT-PCR, while tenascin
and TIMP cDNAs were in vivo excised from a LPS-stimulated
rat macrophage cDNA library (a gift from Dr. Wolfgang North-
eman, TSRI). The techniques for RT-PCR and in vivo excision
have been described previously from our laboratory [19].
cDNA subcloning. The subcloning of the cDNAs for PAl-i
(gift of Dr. T. Gelehrter, University of Michigan, Ann Arbor,
Michigan, USA) and glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) (gift from Dr. R. Wu, Cornell University,
Ithaca, New York, USA) for riboprobe generation have been
described previously [19]. The cDNA for c1-integrin and a1(1II)
collagen were gifts from Drs. M.J. Ignatius (University of
California San Francisco, San Francisco, California, USA) and
F.R. Frankel (University of Pennsylvania, Philadelphia, Penn-
sylvania, USA), respectively. The cDNAs were subcloned into
PGEM vectors for in vitro transcription as previously described
[19].
Rnase protection assay. Kidneys were homogenized in 4 M
GTC with a Tissumizer (Tekmar, Inc., Cincinnati, Ohio, USA).
The RNA was prepared by cesium chloride centrifugation,
quantitated by its absorption at 260 nm, aliquotted, and stored
at —70°C in 70% ethanol. Two micrograms of total RNA were
hybridized for 12 to 16 hours with 1 x l0 counts of either
32PUTP or 32P-CTP labeled anti-sense nboprobe at 56°C. The
radiolabeled anti-sense rat riboprobes were prepared by in vitro
transcription with either T7 [EN, urokinase, tenascin, TIMP,
transin, a1(III) and a2(IV) collagens], SP6 (a1-integrin, GAPDH),
or T3 (PAl- 1) RNA polymerase with the incorporation of either
32P-UTP or 32P-CTP (Amersham, Chicago, Illinois, USA).
Unhybridized RNA was digested with RNase T1 (Ambion,
Austin, Texas, USA) and RNase A (Sigma Chemical Co., St.
Louis, Missouri, USA) at 30°C for one hour. The RNase was
digested with proteinase K (10 mg/mI) at 37°C for 30 minutes.
After phenol/chloroform extraction and sodium acetate/ethanol
precipitation, the samples were denatured and electrophoresed
on 6% polyacrylamide gel. The dried radioactive blots were
scanned on the AMBIS Radioanalytic Imaging System (AMBIS
Inc., San Diego, California, USA) and were then computer
regenerated on the monitor. Rectangles were circumscribed
around the detected bands and the radioactivity within each
rectangle was determined by the computer. After subtraction of
background counts, net radioactivity within each rectangle was
determined and normalized to a square centimeter. Data are
presented as a ratio of specific mRNA/GAPDH mRNA to
equalize the quantity of RNA within each sample.
Western blotting
Renal cortex from control and experimental rats was sus-
pended in 0.5% Triton-X 100 with a Tissumizer (Tekmar).
Twenty-five microliters of SDS-PAGE buffer containing 4%
SDS and 200 mrvi dithiothreitol was added to 25 l of each
sample and was boiled for 10 minutes. A positive control
sample consisted of supernatant from CHO cells transfected
with rat transin cDNA (a gift of Dr. L. Matrisian, Vanderbilt
University, Nashville, Tennessee, USA) [171. All samples were
centrifuged at 14 K for 15 minutes in an Eppendorf microfuge.
The resultant supernatant was electrophoresed on a SDS-
polyacrylamide gel and transferred onto a 0.2 sm nitrocellulose
filter (Schleicher and Schuell, Keene, New Hampshire, USA).
The filter was blocked with 5% nonfat milk and then sequen-
tially incubated with rabbit anti-rat transin synthetic peptide
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antibody (a gift of Dr. L. Matrisian) [171 and alkaline phos-
phatase-conjugated goat anti-rabbit IgG (Boehringer Mann-
heim, Indianapolis, Indiana, USA) at room temperature. The
filter was developed with 5-bromo-4-chloro-3-indolyl phos-
phate/nitro blue tetrazolium and then air dried.
Determination of PAl-i bioactivizy
Whole kidney PA!- I activity was determined by a t-PA
binding assay as described previously [20]. Briefly, renal tissue
from rats immunized with bovine TBM (N = 4) or ovalbumin(N = 4)14days earlier were homogenized in 0.5% Triton X-l00
with a Tissumizer and were frozen at —70°C until assay.
Purified t-PA (0.05 gIwel1) was bound to U-bottom polyvinyl-
chloride microtiter wells (Falcon 3911; Becton Dickinson, Ox-
nard, California, USA) by incubating at 4°C overnight. The
plates in this and each subsequent step were washed with 0.1%
BSA, 0.05% NaN3 and 0.05% Tween 20 in PBS. The wells were
then blocked with 3% BSA (200 pJIwell) for one hour at 37°C.
Test samples and standard curves of purified PAl-I were diluted
in PBS supplemented with 3% BSA, 5 mrs EDTA, 0.1% Tween
80, and 0.02% NaN3, and were then incubated in the t-PA-
coated wells for one hour at 37°C. After washing, bound PAI-l
was detected by the sequential incubation of each well with
rabbit antiserum to PAl- 1, followed by 1251-labeled goat anti-
rabbit IgG (2.5 x i0 to 5 x io cpmlwell) at 37°C. The wells
were excised and the bound radioactivity was determined with
a gamma counter (Micromedics Systems, Horsham, Pennsyl-
vania, USA). Values were normalized for variations in protein
concentration as determined by the assay of Bradford [21] and
represent the mean of duplicate measurements.
Results
Morphologic studies
The histologic evolution of the TIN which develops in this
group of rats following immunization with bovine TBM has
been previously described [22]. There were no gross abnormal-
ities within the kidneys of rats immunized with ovalbumin. By
comparison, rats immunized with bovine TBM developed a
focal inflammatory infiltrate involving 10 to 40% of the cortex
beginning on day 7. This infiltrate extended to involve 60 to 80%
and 80 to 90% of the cortex by days 8 and 9, respectively. The
inflammatory cells were predominantly neutrophils on days 7
(65%) and 8 (80%), but were rapidly replaced by mononuclear
leukocytes, so that less than 5% of the infiltrating cells were
neutrophils by day 10. This was accompanied by tubular
epithelial degeneration and necrosis, disruption of the TBM and
interstitial edema. In addition, foci of fibrosis with the charac-
teristic pattern suggestive of onion skin were present in areas of
infiltrate at the later time point.
Quantitation of steady-state extracellular matrix protein and
adhesion molecule mRNAs
a1-Integrin. The steady-state mRNA expression of a1-inte-
grin in rats with TIN was not significantly different from that of
ovalbumin-immunized rats at the time points examined (Fig. 1).
FN. The FN/GAPDH mRNA ratio in rats with TIN increased
to 1.5 x that of ovalbumin-immunized rats on day 7 and peaked
at 6.2x that of control rats by day 12. On day 14, the ratio was
still five-fold greater than that of control.
a1(IIl) Collagen. There was a 2.7-fold increase in the mRNA
ratio of a1(III)collagen beginning on day 9 in the rats with TIN,
which peaked at 6.3 X that of ovalbumin-immunized rats on day
10. Although declining thereafter, the steady state ratio was still
5.4-fold greater than control rats on day 14.
a2 Collagen IV. In contrast to a1(III)collagen, the increase in
a2(IV)collagen/GAPDH ratio began on day 7 (1 .6x) in rats with
TIN and continued to climb to 3.4x that of ovalbumin-immu-
nized rats by day 14.
Tenascin. The steady-state mRNA ratio of tenascin relative
to GAPDH rapidly increased eight days after immunization
with bovine TBM to two-fold above control values, and pla-
teaued at these values through day 14.
Proteinases and proteinase inhibitors
Transin. Transin mRNA was detected in the total RNA of
CHO cells transfected with rat transin cDNA after standard
overnight exposure. Under the same exposure conditions,
transin mRNA was not detected in the kidneys of either
ovalbumin- or bovine TBM-immunized rats at all time points
studied. However, faint bands consistent with the expected size
of transin mRNA were visualized in the kidneys of rats with
TIN on days 8 and 9 after a 72-hour exposure.
u-PA. There was a decline in the u-PAIGAPDH ratio of rats
with anti-TBM antibody-associated TIN beginning on day 8 to
79% of control values. The ratio achieved a nadir on day 9 at
49% and increased to 62% of ovalbumin-immunized rats by day
10.
PAl-i. The steady state ratio of PAl- 1 relative to GAPDH
rapidly increased to 6.3 x in TIN compared to control values on
day 7, peaked on day 8 (12 x), and was still six-fold greater on
day 14.
TIMP. The TIMP/GAPDH steady state mRNA ratio in rats
with anti-TBM antibody-associated TIN peaked at lix that of
control rats on day 8 and slowly declined thereafter, although
there was still a seven-fold increase on day 14.
Immunohistochemistry
Extracellular matrix. The immunolocalization of collagens I,
III and IV, FN, laminin and HSPG in control ovalbumin-
immunized rats and in rats with TIN on days 8 and 14 are
presented in Figures 2 and 3. Within the kidneys of ovalbumin-
immunized rats, two general patterns of staining for the ECM
proteins were discerned. The first pattern consisted of ECM
proteins limited primarily to the tubular basement membrane
staining in a linear pattern which included collagen IV, HSPG,
and laminin. By comparison, the second pattern localized
within the tubulointerstitial connective tissues and peritubular
capillaries. This latter group included FN as well as collagens I
and III. There were no differences in the pattern or intensity of
immunolabeling for the ECM proteins in the kidneys of control
rats from days 8 through 14.
With the onset of leukocyte infiltration on day 8 in rats with
anti-TBM Ab TIN, there were focal regions of decreased
staining for collagen IV, HSPG, and laminin (Figs. 2 and 3)
along the TBM in regions of active inflammation. In occasional
areas, leukocytes were seen traversing across the TBM with
fragmentation of the TBM. However, by day 14, there was
increased accumulation of collagen IV, HSPG, and laminin
(Figs. 2 and 3) around the TBM, giving it a thickened and
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Fig. 1. The steady-state specific
mRNAIGAPDH mRNA expression of aj-
integrin, FN, cr,(III) collagen, a2(IV)
collagen, tenascin (TNC), urokinase
plasminogen activator (u-PA), plasminogen
activator inhibitor-I (PAl-I), and tissue
inhibitor of metalloproteinase (TIMP). Each
circle represents the mean value of three rats
which were assayed individually. Symbols
are: (•) TIN; (0) control.
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wrinkled appearance. In addition, there was increased accumu-
lation of collagen IV within the peritubular matrix. Similarly,
increased accumulation of collagens I and III restricted to the
interstitiuni was seen on day 14 (Fig. 2) interspersed among the
infiltrating mononuclear leukocytes. In contrast, FN was
present both within the interstitium and focally along the
thickened TBM (Fig. 2).
TIMP. Similar to previous reports [23}, TIMP was faintly
detectable (1+) within the control kidneys, limited primarily to
the glomerular capillary, peritubular capillary endothelial cells,
and Bowman's capsule (Fig. 3). With the development of TIN
on day 8, there was a marked increase in TIMP expression
which localized to the peritubular endothelium and infiltrating
leukocytes. Consistent with the mRNA data, the staining was
most intense on day 8 (4+) at the peak of TIMP mRNA and
declined to 1+ — 2+ by day 14 (Fig. 3).
Western blotting
Transin was not detected in the supernatants of kidney
lysates from ovalbumin- or TBM-immunized rats. Under the
same conditions, a band at 60 K consistent with transin was
present in the supernatant of CHO cells transfected with the
cDNA for rat transin [171.
Determination of PAl-i bioactivity
Whole kidney PAI-l activity was below the limit of detection
of the t-PA binding assay (0.6 pglj.d) in two of the four
ovalbumin-immunized rats on day 14. In the remaining two rats,
PAI-l activity corresponded to 0.22 0.01 pg/tg of protein in
kidney lysate. By comparison, there was an increase in PAI-l
activity to 0.35 0.04 pg/pg of protein in kidney lysate (P =
0.01) in rats with anti-TBM antibody TIN on day 14.
Discussion
Tubulointerstitial fibrosis may result from a perturbation in
the homeostatic balance between matrix accumulation and
proteolytic degradation. The results of the present study sug-
gest that this pathologic condition results from a combination of
?•
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Fig. 2. Photomicrographs of immunoperoxidase staining for collagen I, collagen III, collagen IV, and FN in the kidneys of rats immunized with
ovalbumin (control) or bovine TBM on days 8 and 14. In the control group, the deposits were confined to the peritubular capillary area (collagens
I, III, FN) and TBM (collagen IV). During inflammation on days 8 and 14, collagens I and III increased in the area of interstitial infiltration.
Collagen IV was decreased at day 8 in some areas of acute inflammation and was increased at day 14 both in the TBM and, to a lesser extent, in
the adjacent interstitial tissue. FN increased in patterns similar to all three collagens. Original magnification X 400.
increased synthesis of matrix components and probably de-
creased degradation. We found increased synthesis of the
matrix proteins HSPG, tenascin, FN, laminin, and types I, III
and IV collagens to be associated with suppressed expression of
the proteinase, u-PA, in a model of anti-TBM antibody TIN.
Although transin mRNA was detected on days 8 and 9, this did
not correlate with appearance of the protein. In contrast to the
proteinases, the expression of the proteinase inhibitors (TIMP
and PAl-i) was increased.
These findings are consistent with those reported in intersti-
tial fibrosis associated with chronic purine aminonucleoside
nephrosis and unilateral ureteral obstruction [23, 24]. In the
latter model, increased collagen production and decreased
collagenolytic activity has been proposed as a mechanism for
interstitial fibrosis [24]. Similarly, Jones and coworkers re-
ported increased expression of ECM proteins in the tubuloin-
terstitium which was associated with no change in transin or
interstitial collagenase mRNA levels, but increased TIMP,
following aminonucleoside administration [23]. Interestingly,
they found a low level of transin mRNA within the normal
kidney while we were unable to detect its presence. This
discrepancy may relate to the relatively nonspecific rabbit
stromelysin DNA probe used in their Northern analysis. How-
ever, we were able to detect low levels of transin with a
species-specific RNA probe in rats with anti-TBM antibody-
associated TIN on days 8 and 9. Nonetheless, the mRNA did
not correlate with the results of our Western blot, which either
reflects low levels of transin expression or suppression of
translation.
In preliminary studies, we have found increased expression
of multiple growth factors including bFGF, PDGF-B, TGF-f31
and TGF-a in anti-TBM antibody-associated TIN which is
Collagen I
Collagen III
Collagen IV
Fibronectin
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Fig. 3. Photomicro graphs of laminin, heparan sulfate proteoglycan, and TIMP in the kidneys of rats immunized with ovalbumin (control) or
bovine TBM on days 8 and 14. In the control group, laminin and heparan sulfate proteoglycan (HSPG) were confined to the TBM. In the initial
phases of injury on day 8, some decrease was observed when the TBM was involved in acute inflammatory infiltration. By day 14, both laminin
and HSPO had increased in the thickened TBM; however, they were not as prominent in the interstitium as collagen IV. Small amounts of TIMP
were seen in peritubular capillaries in control ovalbumin-injected rats. At day 8 after bovine TBM injection, strong staining for TIMP was found
in areas of cellular infiltration. This declined by day 14. Original magnification X 400.
temporally associated with the data reported in this study [15].
These growth factors were initially detected by mRNA analysis
and/or immunohistochemistry on day 8 and remained elevated
through day 14. In vitro, TGF-131 stimulates the synthesis of
FN, proteoglycans, and collagen [11—131, while PDGF in-
creases proteoglycan production [25] and stimulates the con-
traction of collagen matrices [26]. In vivo the administration of
neutralizing antibodies to TGF-/31 and PDGF decreases focal
mesangial matrix accumulation in mesangioproliferative gb-
merulonephritis [27, 28]. Although we do not demonstrate
causation, the activities of TGF-f31 and PDGF in vitro, as well
as the results of neutralization studies in mesangioproliferative
GN, suggest that they may be mediating the matrix accumula-
tion in anti-TBM antibody-associated TIN.
In addition to stimulating the synthesis of ECM, growth
factors may prevent matrix degradation by inhibiting the syn-
thesis of proteinase. Thus, PDGF, EGF, and bFGF increase
collagenase and/or transinlstromelysin mRNA and activity [29,
30], while TGF-13 inhibits collagenase transcription in vitro [14]
with the effect of TGF-a not having been characterized. Simi-
larly, TGF-f3 suppresses the bFGF-induced increase in u-PA
activity, which is an integral component of the proteolytic
cascade, by indirectly activating the metalloproteinases through
the generation of plasmin [31]. u-PA may also degrade ECM in
the absence of plasmin, suggesting a direct proteolytic effect
[32]. The decrease in u-PA mRNA beginning on day 8 and
persisting through day 14 in the present study is consistent with
these in vitro observations. Thus, the net effect of these
interactions results in the suppression of proteinase production
and activation, resulting in decreased ECM degradation.
The accumulation of excess matrix in anti-TBM antibody-
associated TIN may be further exacerbated by the effect of
growth factors on proteinase inhibitors. In contrast to their
opposing effects on metalloproteinase expression, bFGF, EGF
and TGF-/3 all induce PAl-i and TIMP expression [14, 30, 31,
33]. PAl-i effectively inhibits activation of the metalloprotein-
ase by preventing plasmin generation by u-PA, while TIMP
inhibits matrix degradation by tightly binding to the activated
metalloproteinase [34—37]. Indeed, PAl-i has been shown to be
a potent inhibitor of ECM degradation by malignant cells [38].
Similarly, decreased TIMP expression has been associated with
increased coliagenase activity in metastatic cells [39]. Our
present data are consistent with these findings, since increased
TIMP and PAl- 1 expression correlated with increased matrix
accumulation. Furthermore, the increase in PAl-i steady-state
mRNA expression correlates with increased bioactivity as
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determined by a t-PA binding assay. Finally, we demonstrate,
by immunohistochemistry, the major source of TIMP to be
infiltrating mononuclear leukocyte and peritubular endothelial
cells, which is consistent with previous in vitro data [40].
In conclusion, the present study demonstrates a temporal
association between excess matrix accumulation and both a
decrease or an absence of proteinases, which normally function
to degrade matrix proteins, as well as an increase in their
inhibitors. The exact contribution of the proteinase/inhibitor
relationship to the excess matrix accumulation must await
manipulation studies which may also help to evaluate the
potential therapeutic role of altering proteinase activity.
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